Published in Blood on May 15, 2000
Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma. Clin Cancer Res (2015) 2.00
Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. J Mol Biol (2007) 1.48
Effect of B-cell depletion on viral replication and clinical outcome of simian immunodeficiency virus infection in a natural host. J Virol (2009) 1.09
Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma. P T (2010) 1.03
B cell depletion in autoimmune disease. Arthritis Res Ther (2003) 1.03
Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies? J Clin Immunol (2002) 1.01
Does rituximab treat recurrent focal segmental glomerulosclerosis post-renal transplantation? Pediatr Nephrol (2006) 0.98
Rituximab: mechanisms and applications. Br J Cancer (2001) 0.96
New therapies for rheumatoid arthritis. Clin Exp Immunol (2005) 0.95
Small Bowel Lymphoma. Curr Treat Options Gastroenterol (2003) 0.94
New therapies for systemic lupus erythematosus. Clin Exp Immunol (2005) 0.92
Inverse hormesis of cancer growth mediated by narrow ranges of tumor-directed antibodies. Proc Natl Acad Sci U S A (2014) 0.91
Internalizing cancer antibodies from phage libraries selected on tumor cells and yeast-displayed tumor antigens. J Mol Biol (2010) 0.89
Rituximab responsive immune thrombocytopenic purpura in an adult with underlying autoimmune lymphoproliferative syndrome due to a splice-site mutation (IVS7+2 T>C) affecting the Fas gene. Eur J Haematol (2007) 0.88
A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. Leukemia (2009) 0.87
Comparability analysis of anti-CD20 commercial (rituximab) and RNAi-mediated fucosylated antibodies by two LC-MS approaches. MAbs (2013) 0.86
Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis. Arthritis Res Ther (2003) 0.85
Two cases of interstitial pneumonitis caused by rituximab therapy. Korean J Intern Med (2006) 0.85
B cell non-Hodgkin's lymphoma: rituximab safety experience. Arthritis Res Ther (2005) 0.84
Innovative strategies in lymphoma therapy. Wien Klin Wochenschr (2003) 0.81
In vivo, multimodal imaging of B cell distribution and response to antibody immunotherapy in mice. PLoS One (2010) 0.81
Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry study. Leukemia (2014) 0.81
Role of consolidation with yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma. Ther Adv Hematol (2014) 0.79
Diffuse large B-cell lymphoma mimicking advanced basal cell carcinoma. J Natl Med Assoc (2007) 0.79
Discovery of internalizing antibodies to tumor antigens from phage libraries. Methods Enzymol (2012) 0.77
Indications for use and safety of rituximab in childhood renal diseases. Pediatr Nephrol (2012) 0.77
Hormesis in cancer immunology: Does the quantity of an immune reactant matter? Oncoimmunology (2014) 0.76
Physicochemical Evaluation of Lyophilized Formulation of p-SCN-Bn-DOTA- and p-SCN-Bn-DTPA-rituximab for NHL Radio Immunotherapy. Iran J Pharm Res (2016) 0.75
C-MOPP: the forgotten regimen plus Rituximab for untreated and relapsed follicular lymphoma. Am J Blood Res (2011) 0.75
Antibody-targeted paclitaxel loaded nanoparticles for the treatment of CD20(+) B-cell lymphoma. Sci Rep (2017) 0.75
Effects of discrimination by sex and race on the early careers of British medical graduates during 1981-7. BMJ (1990) 12.33
Audit of admission to medical school: I--Acceptances and rejects. Br Med J (Clin Res Ed) (1984) 8.31
The changing clinical experience of British medical students. Lancet (1993) 6.85
Audit of admission to medical school: II--Shortlisting and interviews. Br Med J (Clin Res Ed) (1984) 5.62
Prospective survey of performance of medical students during preclinical years. Br Med J (Clin Res Ed) (1986) 5.59
Medical school applicants from ethnic minority groups: identifying if and when they are disadvantaged. BMJ (1995) 5.46
Admission to medical school. Br Med J (Clin Res Ed) (1985) 4.90
Clinical experience of UK medical students. Lancet (1998) 4.83
Intercalated degrees, learning styles, and career preferences: prospective longitudinal study of UK medical students. BMJ (1999) 4.58
Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer (2003) 4.22
Clinical experience, performance in final examinations, and learning style in medical students: prospective study. BMJ (1998) 4.09
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol (1996) 4.07
Prospective study of the disadvantage of people from ethnic minority groups applying to medical schools in the United Kingdom. BMJ (1989) 3.91
Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med (1987) 3.52
Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ (1989) 3.32
Save our service. BMJ (1997) 2.98
Audit of admission to medical school: III--applicants' perceptions and proposals for change. Br Med J (Clin Res Ed) (1984) 2.78
Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer. Ann Intern Med (1990) 2.64
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis (2008) 2.55
Admission for medicine in the United Kingdom: a structural model of background factors. Med Educ (1986) 2.53
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol (1998) 2.52
Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann Oncol (2014) 2.50
Choice and ordering of medical school applications: cause for concern. Lancet (1987) 2.36
Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med (1990) 2.32
Retrievable inferior vena caval filter for thromboembolic disease in pregnancy. Br J Obstet Gynaecol (1997) 2.01
Treatment of patients with cancer of an unknown primary site. N Engl J Med (1993) 2.00
British doctors are not disappearing. BMJ (1997) 1.99
Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol (1997) 1.97
Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med (1986) 1.90
Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2011) 1.84
Small cell lung cancer. Complete remission and improved survival. Am J Med (1979) 1.83
Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol (1995) 1.80
Detection of a point mutation in NQO1 (DT-diaphorase) in a patient with colon cancer. J Natl Cancer Inst (1995) 1.79
Comatose patients smelling of alcohol. BMJ (1989) 1.79
Measurement of intracranial pressure in children: a critical review of current methods. Dev Med Child Neurol (2007) 1.79
Final examination performance of medical students from ethnic minorities. Med Educ (1996) 1.70
Pain related to the psoas muscle after total hip replacement. J Bone Joint Surg Br (2002) 1.68
The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small-cell lung cancer. J Clin Oncol (1986) 1.67
Preoperative combined modality therapy with paclitaxel, carboplatin, prolonged infusion 5-fluorouracil, and radiation therapy in localized esophageal cancer: preliminary results of a Minnie Pearl Cancer Research Network phase II trial. Cancer J Sci Am (1999) 1.67
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum (2008) 1.66
Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. J Clin Oncol (1997) 1.62
European League Against Rheumatism recommendations for the inclusion of patient representatives in scientific projects. Ann Rheum Dis (2011) 1.59
Managing medical mishaps. BMJ (1996) 1.58
Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up. Clin Endocrinol (Oxf) (2005) 1.55
What outcomes from pharmacologic treatments are important to people with rheumatoid arthritis? Creating the basis of a patient core set. Arthritis Care Res (Hoboken) (2010) 1.53
Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol (2001) 1.52
Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group. J Clin Oncol (1993) 1.51
Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study. J Clin Oncol (1994) 1.48
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol (2003) 1.48
Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity. Ann Intern Med (1988) 1.47
Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol (1998) 1.46
Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol (1989) 1.46
High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma. J Clin Oncol (1990) 1.46
Paclitaxel administered by a 1-hour infusion: A phase I-II trial comparing two schedules. Cancer J Sci Am (2006) 1.44
A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium. Ann Oncol (1996) 1.43
Etoposide kinetics in patients with obstructive jaundice. J Clin Oncol (1990) 1.43
Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol (1998) 1.42
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol (1996) 1.41
Short-listing of applicants from UCCA forms: the structure of pre-selection judgements. Med Educ (1989) 1.39
Preliminary results from the third flight of the Millimeter Anisotropy Experiment (MAX). Proc Natl Acad Sci U S A (1993) 1.39
Vinorelbine: a new antineoplastic drug for the treatment of non-small-cell lung cancer. Ann Pharmacother (1996) 1.38
University hospitals and the NHS review. BMJ (1990) 1.38
Current concepts in cancer: small-cell lung cancer. N Engl J Med (1979) 1.37
Pseudo-Gaucher cells in multiple myeloma. Am J Med (1979) 1.35
Predominant role of active versus facilitative glucose transport for glucagon-like peptide-1 secretion. Diabetologia (2012) 1.35
A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol (1999) 1.32
Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative. Ann Rheum Dis (2008) 1.32
Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome. Ann Intern Med (1986) 1.32
Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol (1986) 1.31
Evaluation of 99m Tc-DTPA for the measurement of glomerular filtration rate. J Nucl Med (1972) 1.30
Medical schools and racial discrimination. Comparison between medical schools is unjustified. BMJ (1995) 1.30
Measurement of rectal electrical potential difference as an instant screening-test for hyperaldosteronism. Lancet (1970) 1.28
Metastatic breast cancer confined to the skeletal system. An indolent disease. Am J Med (1986) 1.28
Patient perspective of measuring treatment efficacy: the rheumatoid arthritis patient priorities for pharmacologic interventions outcomes. Arthritis Care Res (Hoboken) (2010) 1.28
Departmental divisions and the crisis in undergraduate medical education. Br Med J (Clin Res Ed) (1988) 1.28
Combined small-cell and non-small-cell lung cancer. J Clin Oncol (1989) 1.26
Small-cell lung cancer. A curable disease. Cancer Chemother Pharmacol (1980) 1.24
Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol (1991) 1.22
A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol Oncol (2006) 1.22
The role of maintenance therapy in disseminated testicular cancer. N Engl J Med (1981) 1.22
Long-term outcome in children with temporal lobe seizures. III: Psychiatric aspects in childhood and adult life. Dev Med Child Neurol (1979) 1.21
Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin Oncol (1995) 1.20
Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol (1993) 1.20
Chronic daily administration of oral etoposide--a phase I trial. J Clin Oncol (1989) 1.20
A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma. Br J Cancer (2010) 1.19
Randomized comparison of two combination regimens versus minimal chemotherapy in nonsmall-cell lung cancer: a Southeastern Cancer Study Group Trial. J Clin Oncol (1990) 1.19
Clinical investigation of the effects of adrenal corticosteroid excess on the colon. Lancet (1969) 1.18
Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities. J Clin Oncol (1997) 1.18
Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J Clin Oncol (1992) 1.17
Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol (2001) 1.16
Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days. Eur J Cancer (1994) 1.15
Extragonadal germ cell tumors and unrecognized germ cell tumors. Semin Oncol (1992) 1.15
Academic medical staff changes in England and Wales 1984-87. Lancet (1987) 1.14
Desmopressin urine concentration test. Br Med J (1978) 1.14
Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer. J Clin Oncol (1988) 1.14
Thallium-201 for medical use. I. J Nucl Med (1975) 1.13